Advanced UroScience
This article was originally published in The Gray Sheet
Executive Summary
Minnesota federal judge dismisses suit against the firm and founder Timothy Lawin Sept. 30. Brought by Uroplasty in August 1998, the suit alleged that Lawin had misappropriated Uroplasty's pyrolytic, carbon-coated micro-bead technology for use in the Durasphere injectable stress urinary incontinence product. Durasphere was approved by FDA Sept. 13 (1"The Gray Sheet" Sept. 27, p. 14). U.S. district court Judge Michael Davis rules that Uroplasty failed to show evidence that the firm was ever involved with the development of the technology
You may also be interested in...
Advanced UroScience Durasphere Post-Approval Study Focuses On Durability
Advanced UroScience's post-approval study of its Durasphere bulking agent for treatment of female stress urinary incontinence due to intrinsic sphincter deficiency will focus on evaluating the durability of the product, the company reports.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.